Survival
Study	Topotecan group	Paclitaxel group	RR	P value
Survival (median/range by week)
Huinink 2004	63.0 (range <1 to 238.4+ weeks; 20.5% censored)	53.0 (range <1 to 226.3+ weeks; 12.3% censored)		0.44
Long‐term median survival‐platium‐refractory (by week)
Huinink 2004	28.4	39.7
long‐term median survival‐platium‐early/interim relapse (by week)
Huinink 2004	71.9	35.0
Long‐term median survival‐platium‐late relapse(by week)
Huinink 2004	63.4	85.1